Estimation of the incidence of a rare genetic disease through a two-tier mutation survey.
Recent attempts to detect mutations involving single base changes or small deletions that are specific to genetic diseases provide an opportunity to develop a two-tier mutation-screening program through which incidence of rare genetic disorders and gene carriers may be precisely estimated. A two-tier survey consists of mutation screening in a sample of patients with specific genetic disorders and in a second sample of newborns from the same population in which mutation frequency is evaluated. We provide the statistical basis for evaluating the incidence of affected and gene carriers in such two-tier mutation-screening surveys, from which the precision of the estimates is derived. Sample-size requirements of such two-tier mutation-screening surveys are evaluated. Considering examples of cystic fibrosis (CF) and medium-chain acyl-CoA dehydrogenase deficiency (MCAD), the two most frequent autosomal recessive disease in Caucasian populations and the two most frequent mutations (delta F508 and G985) that occur on these disease allele-bearing chromosomes, we show that, with 50-100 patients and a 20-fold larger sample of newborns screened for these mutations, the incidence of such diseases and their gene carriers in a population may be quite reliably estimated. The theory developed here is also applicable to rare autosomal dominant diseases for which disease-specific mutations are found.
Center for Demographic and Population Genetics, University of Texas Graduate School of Biomedical Sciences, Houston 77225.
R
R
Chakraborty
M R
MR
Srinivasan
S
S
Raskin
D042964:Acyl-CoA Dehydrogenase; D044944:Acyl-CoA Dehydrogenases / Q000172:deficiency*; D003550:Cystic Fibrosis / Q000235:genetics*; D005808:Genes, Recessive; D005828:Genetics, Population; D006579:Heterozygote; D006801:Humans; D015994:Incidence; D008957:Models, Genetic; D009154:Mutation
D044944:Acyl-CoA Dehydrogenases; D042964:Acyl-CoA Dehydrogenase